Completed PHASE2 INTERVENTIONAL NCT00043303

Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis

A Multicenter Study of the Safety and Anti-Fibrotic Efficacy of Interferon-Gamma 1b (Actimmune) in Patients With Severe Lever Fibrosis or Compensated Cirrhosis Due to Hepatitis C.

Sponsor: InterMune

Conditions Cirrhosis Liver Fibrosis

Interventions interferon gamma-1b

Updated 5 times since 2017 Last updated: Oct 29, 2007 Started: Sep 30, 2001 Completion: Nov 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Cirrhosis and Liver Fibrosis, this trial is completed. The trial is conducted by InterMune and has accumulated 5 data snapshots since 2001. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

InterMune

Data source: InterMune

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.